(Q38089846)

28 August 2017

title

Neuropathic pain: strategies in drug discovery and treatment (English)

1 reference

28 August 2017

0 references

1 reference

P Yogeeswari

1

1 reference

28 August 2017

J Vaigunda Ragavendran

series ordinal

2

1 reference

28 August 2017

D Sriram

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Drug Discovery

28 August 2017

published in

1 reference

28 August 2017

volume

2

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

169-184

1 reference

Animal and cellular models of chronic pain

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Neuronal plasticity: increasing the gain in pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Neuropathic pain: aetiology, symptoms, mechanisms, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Pathophysiological mechanisms of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Immune and inflammatory mechanisms in neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Pharmacotherapy for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

A new view on how AMPA receptors and their interacting proteins mediate neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

TRPV1 antagonists as a potential treatment for hyperalgesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

The role of sodium channels in chronic inflammatory and neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Targeting chronic and neuropathic pain: the N-type calcium channel comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Centrally-mediated antinociceptive actions of GABA(A) receptor agonists in the rat spared nerve injury model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Antiepileptics and the treatment of neuropathic pain: evidence from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

The effects of GABA(B) agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Antidepressant drugs as adjuvant analgesics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Antidepressants in the treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Peripherally administered amitriptyline derivatives have differential anti-allodynic effects in a rat model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Venlafaxine in neuropathic pain following treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Evidence for an antihyperalgesic effect of venlafaxine in vincristine-induced neuropathy in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

NMDA receptors as targets for drug action in neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Increased cold allodynia following intrathecal N-methyl-D-aspartate in rats with a mononeuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Antiallodynic effects of NMDA glycine(B) antagonists in neuropathic pain: possible peripheral mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

SYM-2081 a kainate receptor antagonist reduces allodynia and hyperalgesia in a freeze injury model of neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Purine-mediated signalling in pain and visceral perception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

The capsaicin receptor: a heat-activated ion channel in the pain pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

TRP channels as cellular sensors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

The cloned capsaicin receptor integrates multiple pain-producing stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Sodium channels and mechanisms of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Reversal of neuropathic pain by alpha-hydroxyphenylamide: a novel sodium channel antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Calcium channels as therapeutic targets in neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Design, synthesis, and preliminary pharmacological evaluation of 4-aminopiperidine derivatives as N-type calcium channel blockers active on pain and neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

(S)-4-Methyl-2-(methylamino)pentanoic acid [4, 4-bis(4-fluorophenyl)butyl]amide hydrochloride, a novel calcium channel antagonist, is efficacious in several animal models of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

A single intrathecal injection of GABA permanently reverses neuropathic pain after nerve injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

Mechanical allodynia following contusion injury of the rat spinal cord is associated with loss of GABAergic inhibition in the dorsal horn

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

The effect of spinal GABA receptor agonists on tactile allodynia in a surgically-induced neuropathic pain model in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.2.169

21 January 2018

Identifiers

DOI

10.1517/17460441.2.2.169

1 reference

28 August 2017

1 reference